Dasher Neuroscience Completes Patient Enrollment in Phase 2 Global Clinical Trial of Lead AI Drug Candidate YA-101 for Multiple System Atrophy (MSA)

Summary

Dasher Neuroscience completed patient enrollment in a Phase 2 global clinical trial of YA-101, its lead AI drug candidate for Multiple System Atrophy. This represents a significant milestone in the development of the CNS-focused therapeutic program.